The PreOncology Institute
The oncology expertise, evidence evaluation, and physician oversight that powers the PreOncology Program™.
What We Do
The Institute conducts original research in Stage Alpha detection, including liquid biopsy interpretation, multi-omic risk modeling, and longitudinal biomarker validation. Our findings directly inform the clinical protocols deployed across the PreOncology Program.
The Institute is also responsible for the Signal Board, the board-certified oncologist review function that evaluates ambiguous or elevated findings from member surveillance, and provides a clear, clinical path forward for both the member and their primary care physician.
We provide continuing medical education for physicians pursuing PreOncologist certification, covering advanced risk assessment, emerging detection technologies, and evidence-based prevention protocols.
The Discipline of PreOncology
PreOncology is the medical discipline dedicated to detecting, interpreting, and intervening at the earliest stage at which cancer can be definitively identified. It does not require that cancer be invisible or pre-symptomatic. It requires only that it be caught at the earliest point the Stage Alpha Operating System™ (patent pending) can make a confident, actionable determination.
Conventional oncology asks what stage a cancer has reached. PreOncology asks something different: given what we know about this individual’s biology, what is the earliest point at which we can act with confidence? That shift in question is what separates surveillance from prevention.
The Role of the PreOncologist
A PreOncologist is a board-certified medical oncologist with additional expertise in cancer prevention, early detection, and signal interpretation, who has successfully completed the PreOncology Certification Process.
Domain
Responsibilities
Risk Stratification
Interpret genomic, molecular, imaging, and clinical data to build individualized cancer risk profiles using outputs from the Dynamic Risk Engine.
Signal Detection and Adjudication
Evaluate findings from whole genome sequencing, liquid biopsy, imaging, and biochemical panels that meet Stage Alpha signal thresholds. Determine the need for follow-up or intervention.
Clinical Decision-Making
Chair the Signal Board and assign each case to observation, further testing, or referral, based on the composite 0 to 15 scoring system across five clinical dimensions.
Precision Prevention
Design evidence-based prevention and risk-reduction plans that integrate medical, nutritional, and behavioral strategies aligned with the member’s Stage Alpha sub-staging.
Member Communication
Deliver predictive findings clearly and responsibly. Coordinate communication back to the primary care physician to maintain care continuity.
Data Feedback
Document clinical outcomes within the Stage Alpha Operating System to support continuous model refinement and learning.
Independent by Design
To maintain scientific integrity, the Institute operates independently from PreOncology’s commercial activities. This separation enables unbiased research, peer-reviewed publication, and partnerships with academic medical centers, ensuring that the clinical protocols guiding the PreOncology Program are held to the same standard as any evidence the program evaluates.